Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AADAT | Q8N5Z0 | 5/20 | 0.52 |
| ▸ | PRCP | P42785 | 1/20 | 0.45 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | PREP | P48147 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3261980 | 1.00 | AADAT (0.52) | AADATPRCPTMEM97SIGMAR1SMN1; SMN2 | |
| SCHEMBL3226009 | 0.84 | AADAT (0.56) | AADATTMEM97SIGMAR1SMN1; SMN2HSD11B1 | |
| SCHEMBL3225994 | 0.84 | AADAT (0.56) | AADATTMEM97SIGMAR1SMN1; SMN2HSD11B1 | |
| SCHEMBL3264197 | 0.81 | SMN1; SMN2 (0.46) | AADATPRCPTMEM97SIGMAR1SMN1; SMN2 | |
| SCHEMBL3264198 | 0.81 | SMN1; SMN2 (0.46) | AADATPRCPTMEM97SIGMAR1SMN1; SMN2 | |
| SCHEMBL14160545 | 0.80 | AADAT (0.50) | AADATTMEM97SIGMAR1HSD11B1PREP | |
| SCHEMBL21206505 | 0.79 | AADAT (0.62) | AADATTMEM97SIGMAR1GFERPREP | |
| SCHEMBL3220063 | 0.78 | AADAT (0.48) | AADATTMEM97SIGMAR1HSD11B1PREP | |
| SCHEMBL3220048 | 0.78 | AADAT (0.48) | AADATTMEM97SIGMAR1HSD11B1PREP | |
| SCHEMBL14117159 | 0.77 | AADAT (0.50) | AADATTMEM97SIGMAR1SMN1; SMN2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100055071-A1 | Anti-Viral Compounds | SMITHKLINE BEECHAM CORPORATION | 2010-03-04 | — | — | US | disclosed |
| US-20080193411-A1 | Anti-viral Compounds | GENELABS TECHNOLOGIES, INC. | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080193411-A1 | Anti-viral Compounds | ZC3HAV1, ZC3HAV1L, SARS1 | AADAT 2338/4885PRCP 983/4885TMEM97 4201/4885 |
| US-20100055071-A1 | Anti-Viral Compounds | ZC3HAV1, ZC3HAV1L, SARS1 | AADAT 2338/4885PRCP 983/4885TMEM97 4201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.